News and Announcements
Riccardo Canevari of Radiopharm Theranostics (ASX:RAD)
- Published December 06, 2022 6:49AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Radiopharm Theranostics (ASX:RAD) is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer, from some of the world’s leading universities and institutes.
Watch this interview with CEO Riccardo Canevari as he discusses how they approach oncology with their unique processes.
Executive Interviews
A New Era of Investment in Australia’s Life Science Sector
In just six months, four new investment funds have emerged, all targeting Australia’s life sciences and healthcare companies. With scientific advancements, government backing, and structural undervaluation, these funds represent a significant moment for the sector—offering investors a rare opportunity to capitalise on growth in biotech and medtech.
Crypto is the winner in the US Election!
The 2024 US election has marked a turning point for cryptocurrency, with both political parties offering bipartisan support, significant donations from the crypto community, and a focus on regulatory clarity. As the industry gains more legitimacy and influence, crypto has become a key player in shaping future economic policies.
122% Returns: The Aussie Crypto Fund Outperforming Bitcoin
In the ever-shifting world of cryptocurrency investments, one fund has made waves by consistently outperforming its peers. This fund has demonstrated a remarkable ability to navigate the volatility of the digital asset market while delivering impressive returns. By employing a combination of strategic risk management, selective investing, and benchmarking against Bitcoin, Merkle Tree Capital has […]
Backed By Leading Investment Groups and Family Offices
